<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:50:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6434884" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6434884</identifier>
        <datestamp>2019-04-08</datestamp>
        <setSpec>trials</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
              <journal-title-group>
                <journal-title>Trials</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1745-6215</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6434884</article-id>
              <article-id pub-id-type="pmcid">PMC6434884</article-id>
              <article-id pub-id-type="pmc-uid">6434884</article-id>
              <article-id pub-id-type="pmid">30909946</article-id>
              <article-id pub-id-type="publisher-id">3270</article-id>
              <article-id pub-id-type="doi">10.1186/s13063-019-3270-2</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Update</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: statistical analysis plan for a randomised controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2108-9222</contrib-id>
                  <name>
                    <surname>Al-Shahi Salman</surname>
                    <given-names>Rustam</given-names>
                  </name>
                  <address>
                    <email>rustam.al-shahi@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Murray</surname>
                    <given-names>Gordon D.</given-names>
                  </name>
                  <address>
                    <email>gordon.murray@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dennis</surname>
                    <given-names>Martin S.</given-names>
                  </name>
                  <address>
                    <email>martin.dennis@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Newby</surname>
                    <given-names>David E.</given-names>
                  </name>
                  <address>
                    <email>d.e.newby@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sandercock</surname>
                    <given-names>Peter A. G.</given-names>
                  </name>
                  <address>
                    <email>peter.sandercock@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sprigg</surname>
                    <given-names>Nikola</given-names>
                  </name>
                  <address>
                    <email>nikola.sprigg@nottingham.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sudlow</surname>
                    <given-names>Cathie L. M.</given-names>
                  </name>
                  <address>
                    <email>cathie.sudlow@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Werring</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <address>
                    <email>d.werring@ucl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>White</surname>
                    <given-names>Philip M.</given-names>
                  </name>
                  <address>
                    <email>phil.white@newcastle.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Whiteley</surname>
                    <given-names>William N.</given-names>
                  </name>
                  <address>
                    <email>william.whiteley@ed.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution>Centre for Clinical Brain Sciences, </institution><institution>University of Edinburgh, </institution></institution-wrap>Chancellor’s Building, 49 Little France Crescent, Edinburgh, EH16 4SB UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution>Usher Institute of Population Health Sciences and Informatics, </institution><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution>Centre for Cardiovascular Science, </institution><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution>Faculty of Medicine &amp; Health Sciences, </institution><institution>University of Nottingham, </institution></institution-wrap>Nottingham, UK </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Institute of Neurology, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution>Institute of Neuroscience and Newcastle University Institute for Ageing, </institution></institution-wrap>Newcastle-upon-Tyne, UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>3</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>3</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>20</volume>
              <elocation-id>183</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>11</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>1</day>
                  <month>3</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s). 2019</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">For adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, it is unclear whether starting antiplatelet therapy modifies the risks of recurrent ICH, major haemorrhagic events, major occlusive vascular events, or a composite of all major vascular events compared to avoiding antiplatelet therapy.</p>
                </sec>
                <sec>
                  <title>Methods/design</title>
                  <p id="Par2">The REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, parallel group, open, assessor-blind, randomised trial comparing starting versus avoiding antiplatelet therapy for adults surviving antithrombotic-associated ICH. Recruitment began on 22 May 2013 and ended on 31 May 2018. Follow-up ended on 30 November 2018. This update to the protocol describes the statistical analysis plan (version 1.7, finalised on 25 January 2019). Database lock and un-blinding occurred on 29 January 2019, after which the un-masked trial statistician conducted the final analyses according to this statistical analysis plan.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">Final results of RESTART will be analysed and disseminated in May 2019.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par4">ISRCTN registry <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN71907627">71907627</ext-link>. Prospectively registered on 25 April 2013.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (10.1186/s13063-019-3270-2) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Secondary prevention</kwd>
                <kwd>antiplatelet therapy</kwd>
                <kwd>stroke</kwd>
                <kwd>intracerebral haemorrhage</kwd>
                <kwd>randomised controlled trial</kwd>
                <kwd>statistical analysis plan</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>British Heart Foundation (GB)</institution>
                  </funding-source>
                  <award-id>SP/12/2/29422</award-id>
                  <award-id>FS/13/72/30531</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>Rustam</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par13">Patients with stroke due to spontaneous intracerebral haemorrhage (ICH) often have past histories of vascular disease and people who survive ICH are at risk of vaso-occlusive events [<xref ref-type="bibr" rid="CR1">1</xref>]. When patients develop ICH whilst taking antithrombotic (antiplatelet or anticoagulant) drugs for the prevention of vaso-occlusive disease, these drugs are usually immediately discontinued because of the risk of ICH growth in the 24 h after symptom onset [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>]. If these patients survive the early consequences and complications of the ICH, secondary prevention of vaso-occlusive disease is an important consideration for many survivors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Blood pressure lowering is effective for the prevention of stroke after ICH [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
              <p id="Par14">However, it is unknown whether survivors of ICH that occurred whilst taking antithrombotic drugs should start or avoid antiplatelet drugs for continued secondary prevention. A recent systematic review and meta-analysis of observational studies of all sub-types of intracranial haemorrhage found lower risks of ischaemic events and no difference in haemorrhagic events associated with antiplatelet drug resumption [<xref ref-type="bibr" rid="CR9">9</xref>]. Small, non-randomised observational studies restricted to patients with stroke due to ICH have reported similar associations [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR14">14</xref>], but these associations were not ‘dramatic’ so randomised controlled trials (RCTs) are needed to resolve this therapeutic dilemma [<xref ref-type="bibr" rid="CR15">15</xref>]. However, such RCTs have not been published [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, we designed the REstart or STop Antithrombotics Randomised Trial (RESTART) to determine whether antiplatelet drugs increase the risk of recurrent symptomatic ICH to an extent that might outweigh any beneficial reduction in vaso-occlusive disease [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
            </sec>
            <sec id="Sec2">
              <title>Methods/Design</title>
              <sec id="Sec3">
                <title>Trial design</title>
                <p id="Par15">The primary objective of this parallel group, open, assessor-blind, randomised trial is to estimate the relative and absolute effects of a policy of starting antiplatelet drugs versus avoiding antiplatelet drugs on the risk of recurrent symptomatic ICH after spontaneous ICH. We intended to recruit 720 participants (based on the sample size calculation described in the protocol [<xref ref-type="bibr" rid="CR17">17</xref>]) and allocate them 1:1 to each treatment group using a minimisation algorithm based on five variables collected beforehand, namely (1) qualifying ICH location (lobar versus non-lobar, based on local investigator’s interpretation of scan); (2) time since ICH symptom onset (1–6 days, 7–30 days, &gt; 30 days); (3) antiplatelet drug(s) that the patient’s physician would start if allocated (aspirin alone versus other antiplatelet regimen, including combination treatment); (4) participant age at randomisation (&lt; 70 years vs. 70 years or older); and (5) predicted 6-month outcome (predicted probability of good outcome &lt; 0.15 vs. ≥ 0.15 [<xref ref-type="bibr" rid="CR18">18</xref>]). Since the primary objective of the trial is to estimate a treatment effect, the trial does not fit into a conventional superiority, equivalence or non-inferiority hypothesis testing framework.</p>
                <p id="Par16">RESTART collected all participants’ diagnostic brain imaging (usually computed tomography (CT), but sometimes magnetic resonance imaging (MRI) alone) that diagnosed ICH before randomisation. An imaging sub-study was also conducted involving brain MRI performed according to a specific imaging protocol to test for an interaction between imaging biomarkers of cerebral small vessel disease and the effects of antiplatelet drugs. The RESTART imaging panel collected radiographic data from these imaging studies, masked to treatment allocation group [<xref ref-type="bibr" rid="CR17">17</xref>]. The analysis of the imaging sub-studies will be largely exploratory. The MRI sub-study will test hypotheses about microbleeds and explore hypotheses about other modifiers of the effect of antiplatelet drugs. The diagnostic CT imaging study will explore hypotheses about modifiers of the effect of antiplatelet drugs.</p>
              </sec>
              <sec id="Sec4">
                <title>Statistical interim analyses and stopping guidance</title>
                <p id="Par17">The final Data Monitoring Committee charter (version 1.6, 28 March 2014) did not specify a formal fixed schedule of interim analyses, but allowed the Data Monitoring Committee to advise the chair of the Trial Steering Committee and the sponsor if there was ‘proof beyond reasonable doubt’ that might also reasonably be expected to influence clinical practice. Application of this ‘overwhelming evidence’ principle makes adjustment of the final level of statistical significance testing unnecessary [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>Trial population</title>
                <p id="Par18">We did not ask collaborators at participating sites to record every patient they screened for eligibility, although some sites’ standard practice was to do this anyway, which enabled us to investigate reasons for non-recruitment of eligible patients at these sites [<xref ref-type="bibr" rid="CR22">22</xref>]. We asked collaborators to report and record every patient for whom written informed consent was obtained, so we will report the numbers of patients with consent who were either randomised or not (with reasons). Participants found to be ineligible after randomisation will be quantified and categorised according to the eligibility criteria in the protocol [<xref ref-type="bibr" rid="CR17">17</xref>], but they will be analysed in the treatment group to which they were allocated. Because RESTART uses multiple overlapping sources of ascertainment of outcomes during follow-up [<xref ref-type="bibr" rid="CR17">17</xref>], we will only withdraw participants from analyses if the participant or their representative requests complete withdrawal from all methods of follow-up after randomisation. We will analyse data collected on the participant up to the point of withdrawal. We will not regard participants who change their allocated treatment as premature withdrawals. We will quantify adherence to the allocated treatment at hospital/clinic discharge after randomisation, and at the time of each subsequent follow-up postal/telephone questionnaire assessment (first done at 6 or 12 months after randomisation and then annually for up to 5 years). We will describe loss to follow-up in two ways. Firstly, we will quantify the proportion of patients without a complete follow-up questionnaire at each planned follow-up time point (first starting 6–12 months after randomisation). Secondly, we will quantify the sum of the total observed person-time for each participant in the trial as a proportion of the sum of their total potential person-time until the last planned trial follow-up questionnaire for that participant [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
              </sec>
              <sec id="Sec6">
                <title>Analysis populations</title>
                <p id="Par19">All analyses will follow the ‘intention-to-treat’ principle in order to fully preserve the benefit of randomisation. The intention-to-treat population will comprise all participants who have been randomised in RESTART, regardless of whether they were subsequently deemed ineligible after independent review of their diagnostic brain imaging. We will include all randomised participants in the analysis (irrespective of whether they adhere to the allocated treatment), all retained in the group to which they were allocated (i.e. ‘as-randomised’). However, in the brain imaging studies within RESTART, imaging may (1) not have proceeded despite consent being obtained; (2) not have been provided; (3) have been undertaken but may have contravened the required protocol; (4) have been undertaken, but was degraded by motion artefact; or (5) have demonstrated that the patient was ineligible for inclusion in RESTART (which precluded collection of ratings by the RESTART Imaging Panel). Therefore, patients will be included in the CT imaging study and the MRI sub-study datasets if their pre-randomisation brain imaging was readable and confirmed their eligibility for RESTART.</p>
              </sec>
              <sec id="Sec7">
                <title>Baseline characteristics</title>
                <p id="Par20">We will summarise the following baseline characteristics overall and by treatment group:<list list-type="bullet"><list-item><p id="Par21">The covariates used in the minimisation algorithm (qualifying ICH location, time since ICH symptom onset, antiplatelet drug(s) that patient’s physician would start if allocated, participant age at randomisation, predicted 6-month outcome)</p></list-item><list-item><p id="Par22">Sex</p></list-item><list-item><p id="Par23">Ethnicity</p></list-item><list-item><p id="Par25">Functional status</p></list-item><list-item><p id="Par26">Modified Rankin scale (mRS) score</p></list-item><list-item><p id="Par27">Co-morbidities</p></list-item><list-item><p id="Par28">Antithrombotic drugs taken before ICH</p></list-item><list-item><p id="Par29">Timing of key events (symptom onset to randomisation, symptom onset to earliest imaging study, earliest imaging study to randomisation, symptom onset to sub-study MRI (if applicable), and sub-study MRI to randomisation (if applicable))</p></list-item><list-item><p id="Par30">Characteristics of the ICH and brain on diagnostic imaging and sub-study MRI (if applicable)<list list-type="bullet"><list-item><p id="Par31">The RESTART imaging panel’s report of CT diagnostic imaging will describe the baseline characteristics of the trial population’s brains (e.g. old vascular lesions, periventricular lucencies and atrophy) and ICH (e.g. location, intraventricular extension, subarachnoid extension, ICH volume and finger-like projections [<xref ref-type="bibr" rid="CR24">24</xref>])</p></list-item><list-item><p id="Par32">The RESTART imaging panel’s report of MRI sub-study protocol-compliant imaging will describe the baseline characteristics of the participants’ brains (e.g. brain microbleed presence/location and burden, old infarcts or haemorrhages, superficial siderosis, white matter hyperintensities, and atrophy) and ICH (e.g. location, intraventricular extension, subarachnoid extension, and ICH volume). In the MRI sub-study, the focus of our hypothesis will be on testing whether the presence, number or location of brain microbleeds modifies the effect of antiplatelet drugs on the primary outcome, adjusted for the same covariates used in the primary analysis of the entire RCT. For dichotomous analysis, the number of brain microbleeds will be split as 0 or 1 versus 2 or more and for categorical analysis the split will be 0 or 1 versus 2 to 4 versus 5 or more. Brain microbleed location will be grouped as strictly lobar versus other</p></list-item></list></p></list-item></list></p>
              </sec>
              <sec id="Sec8">
                <title>Outcomes</title>
                <p id="Par33">We collected symptomatic outcomes during follow-up without explicit definitions in order to minimise the complexity of the reporting process for participants, their general practitioners, carers and investigators. During the outcome event adjudication process, we were guided by the principles and definitions described by the Standardised Data Collection for Cardiovascular Trials Initiative [<xref ref-type="bibr" rid="CR25">25</xref>]. We classify events as fatal (if they were followed by death within 30 days) or non-fatal (if they were not followed by death within 30 days).<list list-type="bullet"><list-item><p id="Par34">Fatal or non-fatal radiographically or pathologically proven recurrent symptomatic ICH. We define this as the abrupt onset of headache, altered level of consciousness, or focal neurological deficit, anatomically referable to a focal collection of blood predominantly located within the brain parenchyma (diagnosed on brain imaging or at autopsy), which was not attributable to prior trauma or haemorrhagic transformation of an ischaemic stroke. This also applies when neurological deterioration occurs with radiographic or pathological evidence of ICH volume growth early after the qualifying ICH (due to either haematoma expansion or re-bleeding)</p></list-item><list-item><p id="Par35">Symptomatic spontaneous or traumatic extradural haemorrhage, subdural haemorrhage, subarachnoid haemorrhage, or intraventricular haemorrhage (not accompanying spontaneous ICH)</p></list-item><list-item><p id="Par36">Symptomatic major extracranial haemorrhage (requiring transfusion or endoscopic treatment or surgery, or resulting in death within 30 days, i.e. Bleeding Academic Research Consortium definition for bleeding types 3–5 [<xref ref-type="bibr" rid="CR26">26</xref>])</p></list-item><list-item><p id="Par37">Transient ischaemic attack</p></list-item><list-item><p id="Par38">Ischaemic stroke</p></list-item><list-item><p id="Par39">Acute coronary syndrome (restricted to STEMI and non-STEMI myocardial infarction, but not hospitalisation for unstable angina)</p></list-item><list-item><p id="Par40">Peripheral arterial occlusion</p></list-item><list-item><p id="Par41">Mesenteric ischaemia</p></list-item><list-item><p id="Par42">Retinal arterial occlusion</p></list-item><list-item><p id="Par43">Deep vein thrombosis</p></list-item><list-item><p id="Par44">Pulmonary embolism</p></list-item><list-item><p id="Par45">Revascularisation procedures (carotid, percutaneous coronary intervention or peripheral arterial intervention)</p></list-item><list-item><p id="Par46">Sudden cardiac death with symptoms suggestive of myocardial ischaemia (type 3) or evidence of arrhythmia (i.e. sudden cardiac death [<xref ref-type="bibr" rid="CR25">25</xref>])</p></list-item><list-item><p id="Par47">Symptomatic stroke of uncertain sub-type<list list-type="bullet"><list-item><p id="Par48">Non-fatal stroke, with brain imaging performed too late to distinguish ICH from cerebral infarction</p></list-item><list-item><p id="Par49">Rapidly fatal stroke, but without radiographic or pathological confirmation</p></list-item></list></p></list-item><list-item><p id="Par50">Deaths not due to fatal major vascular events above<list list-type="bullet"><list-item><p id="Par51">Other cardiovascular deaths (e.g. due to heart failure, cardiovascular procedures, cardiovascular haemorrhage)</p></list-item><list-item><p id="Par52">Non-cardiovascular deaths</p></list-item><list-item><p id="Par53">Deaths of undetermined cause</p></list-item></list></p></list-item><list-item><p id="Par54">Annual ratings of participant function completed by participants or their carer using the simplified mRS postal questionnaire [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], or structured telephone interview with non-responders to the postal questionnaire [<xref ref-type="bibr" rid="CR29">29</xref>]</p></list-item></list></p>
                <p id="Par55">The primary outcome is fatal or non-fatal radiographically or pathologically proven recurrent symptomatic ICH. The two key secondary outcomes are a composite of all major haemorrhagic events and a composite of all major vaso-occlusive events (including revascularisation procedures):<list list-type="bullet"><list-item><p id="Par590">The composite secondary outcome of ‘all major haemorrhagic events’ includes the following fatal or non-fatal symptomatic events (that are ‘major’ because of their usual need for hospitalisation and influence on outcome and antithrombotic treatment):<list list-type="bullet"><list-item><p id="Par56">Radiographically or pathologically proven recurrent symptomatic ICH (the primary outcome)</p></list-item><list-item><p id="Par57">Other forms of symptomatic spontaneous or traumatic intracranial haemorrhage, including radiographically or pathologically proven spontaneous or traumatic extradural haemorrhage, subdural haemorrhage, subarachnoid haemorrhage or intraventricular haemorrhage (not accompanying spontaneous ICH)</p></list-item><list-item><p id="Par58">Extracranial haemorrhage at any site requiring transfusion/endoscopic treatment/surgery, or resulting in death</p></list-item></list></p></list-item><list-item><p id="Par59">The composite secondary outcome of ‘all major vaso-occlusive events (including revascularisation procedures)’ includes the following fatal or non-fatal symptomatic events (that are ‘major’ because of their usual need for hospitalisation and influence on outcome and antithrombotic treatment; therefore, we will not include transient ischaemic attack or retinal artery occlusion) or revascularisation procedures:<list list-type="bullet"><list-item><p id="Par60">Fatal or non-fatal vaso-occlusive events, including ischaemic stroke, acute coronary syndrome, mesenteric ischaemia or peripheral arterial occlusion, deep vein thrombosis, or pulmonary embolism</p></list-item><list-item><p id="Par61">Carotid, coronary or peripheral arterial revascularisation procedures</p></list-item></list></p></list-item></list></p>
                <p id="Par62">The composite secondary outcome of ‘all major haemorrhagic or vaso-occlusive events’ combines the two composites defined above. For completeness, the corresponding analysis will also be performed for each composite outcome event proposed in the trial protocol. The interpretation of the trial findings will respect this pre-specified hierarchy of primary outcome, key secondary outcomes and other secondary outcomes, and no formal adjustment will be made to significance levels to allow for multiplicity.</p>
                <p id="Par63">We will summarise the total numbers of the primary and secondary outcomes during follow-up, as well as the number of first events of each type during follow-up, overall and by treatment group.</p>
                <p id="Par64">Serious adverse events are reported in RESTART if they are neither an outcome event nor an expected complication of stroke. Serious adverse events will be grouped by body system and for each event and each grouped set of events, we will quantify the number of events and the number of individuals experiencing at least one such event per allocated treatment group.</p>
                <p id="Par65">We will report adherence (at last follow-up before the occurrence of the first outcome event) to the allocated antiplatelet treatment strategy (start vs. avoid antiplatelet drugs) and use of anticoagulant drugs descriptively per treatment group at discharge and at each annual follow-up. Because blood pressure (BP) control is a potential confounder of the frequency of the primary outcome, the use of BP-lowering drugs at discharge after randomisation and at each annual follow-up will be reported (along with a summary of the available BPs of participants by treatment group).</p>
                <p id="Par66">Any change, divergence or departure from the trial design or procedures defined in the protocol or Good Clinical Practice are identified and recorded as a deviation (if it does not significantly affect a participant’s rights, safety or well-being, or trial outcomes), or a violation (if the deviation may potentially significantly impact the completeness, accuracy and/or reliability of the trial data or that may significantly affect a patient’s rights, safety or well-being). We will list all protocol deviations and violations, but no formal statistical testing will be performed.</p>
              </sec>
              <sec id="Sec9">
                <title>Methods of analysis</title>
                <p id="Par67">In general terms, we will present categorical data using counts and percentages, continuous variables using the mean, median, standard deviation (SD), minimum, maximum, inter quartile points at 25% and 75% (Q1 and Q3), and number of patients with an observation (n). We will estimate the survival function per treatment group using a Kaplan–Meier survival analysis of time to first outcome event during all available follow-up after randomisation. We will censor follow-up at death (unrelated to an outcome event), last available follow-up or voluntary withdrawal from the trial. We will compare the survival function in the two trial arms using a Cox proportional hazards regression model, adjusting for all the covariates included in the minimisation algorithm (qualifying ICH location of lobar versus non-lobar; time since ICH symptom onset of 1–6 days versus 7–30 days versus over 30 days; antiplatelet drug(s) that the patient’s clinician would start if allocated (aspirin alone vs. any other regimen); participant’s age at randomisation (&lt; 70 years vs. ≥ 70 years); predicted probability of a good 6-month outcome (&lt; 0.15 vs. ≥ 0.15)), and presenting the result as an estimated adjusted hazard ratio with its corresponding 95% CI. We will also report the unadjusted estimate of the hazard ratio and its corresponding 95% CI, together with the result of the logrank test. We will estimate the absolute difference in event rates at 1, 2, 3 and 4 years from the Kaplan–Meier analysis.</p>
                <p id="Par68">We will conduct two exploratory sensitivity analyses of our primary analysis, by adding the following secondary outcomes to the primary outcome in the following order, to account for the possibility that some fatalities and non-fatal neurological events without adequate investigation may be recurrent ICH:<list list-type="bullet"><list-item><p id="Par69">Symptomatic stroke of uncertain sub-type</p></list-item><list-item><p id="Par70">Deaths of undetermined cause</p></list-item></list></p>
                <p id="Par71">We will conduct a sensitivity analysis of the secondary outcomes to reflect the cumulative incidence of major haemorrhagic or vaso-occlusive events, using re-randomisation tests [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
                <p id="Par72">We will perform sub-group analyses for the primary outcome and the key secondary outcomes including (1) all major haemorrhagic events, (2) all major vaso-occlusive events (including revascularisation procedures), and (3) the composite of all major haemorrhagic or vaso-occlusive events. We will analyse heterogeneity of treatment effect between sub-groups using statistical tests of interaction. These analyses will be performed by including an interaction term between treatment group and the relevant covariate in the Cox proportional hazards regression model. Time since ICH will be dichotomised in view of the distribution of outcomes in the whole trial dataset. Should any of these adjusted regression models fail to converge, then the corresponding unadjusted analysis will be reported instead. We have specified a priori the following dichotomous sub-groups for the primary analysis:<list list-type="bullet"><list-item><p id="Par73">The five covariates used in the minimisation algorithm<list list-type="bullet"><list-item><p id="Par74">Qualifying ICH location (lobar vs. non-lobar)</p></list-item><list-item><p id="Par75">Time since ICH symptom onset (two subgroups will be defined based on the time from onset being above or below the median time observed in the trial)</p></list-item><list-item><p id="Par76">Antiplatelet drug(s) that the patient’s clinician would start if allocated (aspirin alone vs. any other regimen)</p></list-item><list-item><p id="Par77">Participant’s age at randomisation (&lt; 70 years vs. ≥ 70 years)</p></list-item><list-item><p id="Par78">Predicted probability of a good 6-month outcome (&lt; 0.15 vs. ≥ 0.15)</p></list-item></list></p></list-item><list-item><p id="Par79">Pre-ICH antithrombotic drug regimen (antiplatelet vs. anticoagulant)</p></list-item><list-item><p id="Par80">History of atrial fibrillation documented as a co-morbidity at randomisation (yes vs. no)</p></list-item></list></p>
                <p id="Par81">We will perform a separate analysis for each annual assessment of the mRS score. The analysis at year ‘x’ will be restricted to participants who were randomised at least ‘x’ years prior to study close, to avoid including early deaths in the relevant follow-up year when the corresponding surviving recruits would not have had the potential to be assessed. The analysis will comprise a tabulation of mRS by randomised group, with the formal analysis being based on a Mann–Whitney test. Participants’ type of domicile will be described as categorised on the discharge form and each annual participant questionnaire.</p>
              </sec>
              <sec id="Sec10">
                <title>Statistical principles</title>
                <p id="Par82">We will use available data and not impute data with regard to missing values or withdrawals. We will not perform formal statistical tests of baseline characteristics or adherence by treatment group. All applicable statistical tests will be two-sided and will be performed using a 5% significance level, leading to 95% (two-sided) confidence intervals, unless otherwise specified. We will assess the proportional hazards assumption graphically; if there is strong evidence of violation of the assumption, the impact on the analysis will be assessed by comparing the results of the pre-specified analysis with the results obtained using the restricted survival time approach [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
              </sec>
              <sec id="Sec11">
                <title>Statistical software</title>
                <p id="Par83">The un-blinded trial statistician at the Edinburgh Clinical Trials Unit (ECTU) will perform the statistical programming and analysis to produce all summary tables and figures using the statistical package SAS (v9.3 or a more recent version).</p>
              </sec>
              <sec id="Sec12">
                <title>Quality control</title>
                <p id="Par84">Before database lock and un-blinding, a full statistical report will be produced based on dummy randomisation codes to allow for checking of the data and the proposed summaries/analyses. Isolated data errors detected in the database as a result of quality control checks that are deemed significant will be submitted for enquiry to the trial manager or designee. Systematic data errors in the data reporting will be investigated further; the data will be corrected if necessary, and the appropriate table then re-checked. A random selection of unique analysis and summary tables will be checked using manual methods (i.e. comparison of results in the table to results calculated by a calculator, spreadsheet, database output or any alternative summarisation tool). Checks of statistical analyses will be performed by peer review of program code, log and output. Additionally, the primary outcomes analysis will be replicated independently by a second statistician.</p>
              </sec>
              <sec id="Sec13">
                <title>Administrative information</title>
                <p id="Par85">The published RESTART protocol reflected version 7.0, created on 23 December 2015 [<xref ref-type="bibr" rid="CR17">17</xref>]. The final amendment that was made to the protocol (version 8.0, created on 19 September 2017) was an update to the reference safety information used for clopidogrel. Standard operating procedures produced by the sponsor (<ext-link ext-link-type="uri" xlink:href="http://www.accord.scot/research-access/resources-researchers/sop">http://www.accord.scot/research-access/resources-researchers/sop</ext-link>) guided trial conduct. ECTU standard operating procedures guided the content and format of the final version of the statistical analysis plan (<ext-link ext-link-type="uri" xlink:href="https://www.ed.ac.uk/usher/edinburgh-clinical-trials/supporting-trials/governance/standard-operating-procedures">https://www.ed.ac.uk/usher/edinburgh-clinical-trials/supporting-trials/governance/standard-operating-procedures</ext-link>). This published statistical analysis plan complies with relevant reporting standards and reflects version 1.6 of the statistical analysis plan (see Additional files <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>), which was written and signed by the blinded trial statistician (GDM), was counter-signed by the chief investigator (RA-SS), and included a history of revisions and their timings [<xref ref-type="bibr" rid="CR32">32</xref>]. The definitions of outcome events have been expanded upon in this published version of the statistical analysis plan. The funder and sponsor did not require a data management plan, but plans for data sharing were described in the published protocol [<xref ref-type="bibr" rid="CR17">17</xref>]. The sponsor delegated responsibility for maintaining the trial master file to the trial management group (2013/W/NEU/04/TMF), who keep it in DataStore, which is the University of Edinburgh’s file store for active research data (<ext-link ext-link-type="uri" xlink:href="https://www.ed.ac.uk/information-services/research-support/research-data-service/working-with-data/data-storage">https://www.ed.ac.uk/information-services/research-support/research-data-service/working-with-data/data-storage</ext-link>). The un-blinded trial statistician maintains a paper copy of the statistical master file, which is held securely within ECTU.</p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Discussion</title>
              <p id="Par86">This published version of the final RESTART statistical analysis plan, which we have reported according to recent guidelines [<xref ref-type="bibr" rid="CR32">32</xref>], describes details of our approach to describing the trial population, the statistical principles we will apply to the analysis population, and the analyses we will undertake. We submitted this statistical analysis plan before the end of follow-up and data lock, with one minor modification after the end of follow-up but before database lock and un-blinding, in view of the distribution of outcomes in the entire analysis population. We standardised outcome event definitions before un-masking the trial steering committee to the results [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. This report should provide reassurance about protection of the trial from selective outcome reporting and data-driven analyses.</p>
              <p id="Par87">The results of this trial will help to estimate, for the first time, the effects of antiplatelet drugs on recurrent ICH. This will provide information about the likely net effects of antiplatelet drugs after ICH, and whether a larger RCT will be required to estimate effects on all major vascular events or functional outcome.</p>
            </sec>
            <sec id="Sec15">
              <title>Trial status</title>
              <p id="Par88">Recruitment ended on 31 May 2018. Follow-up ended on 30 November 2018. Data lock occurred on 29 January 2019, after which the un-blinded trial statistician conducted the final analyses according to this statistical analysis plan. The current protocol is version 8.0, created 19 September 2017 (all protocol updates since version 3.0, created 1 February 2013, which was implemented before randomisation began, have been approved by the sponsor and research ethics committee and also communicated to investigators and trial registries). This manuscript is based on version 1.7 of the RESTART statistical analysis plan, finalised on 25 January 2019.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Additional files</title>
              <sec id="Sec16">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="13063_2019_3270_MOESM1_ESM.docx">
                      <label>Additional file 1:</label>
                      <caption>
                        <p>SAP checklist. Reporting checklist: recommended items to address in a clinical trial Statistical Analysis Plan [<xref ref-type="bibr" rid="CR32">32</xref>]. (DOCX 38 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM2">
                    <media xlink:href="13063_2019_3270_MOESM2_ESM.pdf">
                      <label>Additional file 2:</label>
                      <caption>
                        <p>2019_01_25_RESTART SAP_v1.7_signed. Final version of the RESTART statistical analysis plan. (PDF 609 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>BP</term>
                  <def>
                    <p id="Par5">blood pressure</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CT</term>
                  <def>
                    <p id="Par6">computed tomography</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ECTU</term>
                  <def>
                    <p id="Par7">Edinburgh Clinical Trials Unit</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ICH</term>
                  <def>
                    <p id="Par8">intracerebral haemorrhage</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MRI</term>
                  <def>
                    <p id="Par9">magnetic resonance imaging</p>
                  </def>
                </def-item>
                <def-item>
                  <term>mRS</term>
                  <def>
                    <p id="Par10">modified Rankin scale</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RCT</term>
                  <def>
                    <p id="Par11">randomised controlled trial</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RESTART</term>
                  <def>
                    <p id="Par12">REstart or STop antithrombotics randomised trial</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ack>
              <title>Acknowledgements</title>
              <p>Trial steering committee: Professor Colin Baigent (independent chair), Professor Daniel S. Lasserson (independent member), Dr Johanna Carrie (independent patient representative), Professor Rustam Al-Shahi Salman (chief investigator), Professor Gordon D. Murray, Professor Martin S. Dennis, Professor David E. Newby, Professor Peter A.G. Sandercock, Professor Nikola Sprigg, Professor Cathie L.M. Sudlow, Professor David J. Werring, Professor Philip M. White, and Dr. William N. Whiteley.</p>
              <p>Independent data monitoring committee: Dr John Bamford (chair), Professor Jane Armitage, Dr Jonathan Emberson, Professor Gabriël Rinkel, and Professor Gordon Lowe.</p>
              <sec id="FPar1">
                <title>Funding</title>
                <p id="Par89">The trial is funded by a British Heart Foundation special project grant (SP/12/2/29422) and a travel fellowship (FS/13/72/30531). The trial sponsor is the Academic and Clinical Central Office for Research and Development (ACCORD), which is a partnership between the University of Edinburgh and NHS Lothian Health Board.</p>
              </sec>
              <sec id="FPar2" sec-type="data-availability">
                <title>Availability of data and materials</title>
                <p id="Par90">A fully anonymised version of the dataset used for analysis with individual participant data and a data dictionary will be available for other researchers to apply to use one year after publication, via <ext-link ext-link-type="uri" xlink:href="https://datashare.is.ed.ac.uk/handle/10283/3265">https://datashare.is.ed.ac.uk/handle/10283/3265</ext-link>. Written proposals will be assessed by members of the RESTART trial steering committee and a decision made about the appropriateness of the use of data. A data sharing agreement will be put in place before any data will be shared.</p>
              </sec>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>RA-SS and GDM wrote this statistical analysis plan, which was reviewed and approved by the trial steering committee independent chairperson (Prof. Colin Baigent), and the rest of the trial steering committee (MSD, DEN, PAGS, CLMS, PMW, WNW and DJW). RA-SS wrote the first draft of the manuscript. All authors read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="COI-statement">
              <sec id="FPar3">
                <title>Ethics approval and consent to participate</title>
                <p>The Scotland A research ethics committee approved RESTART before recruitment began (reference 12/SS/0138).</p>
              </sec>
              <sec id="FPar4">
                <title>Consent for publication</title>
                <p>Not applicable.</p>
              </sec>
              <sec id="FPar5">
                <title>Competing interests</title>
                <p>The authors declare that they have no competing interests.</p>
              </sec>
              <sec id="FPar6">
                <title>Publisher’s Note</title>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </sec>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Poon</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Fonville</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis</article-title>
                  <source>J Neurol Neurosurg Psychiatry</source>
                  <year>2014</year>
                  <volume>85</volume>
                  <issue>6</issue>
                  <fpage>660</fpage>
                  <lpage>667</lpage>
                  <pub-id pub-id-type="doi">10.1136/jnnp-2013-306476</pub-id>
                  <?supplied-pmid 24262916?>
                  <pub-id pub-id-type="pmid">24262916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Frantzias</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Lyden</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Battey</surname>
                      <given-names>TWK</given-names>
                    </name>
                    <name>
                      <surname>Ayres</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Goldstein</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Mayer</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Steiner</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data</article-title>
                  <source>Lancet Neurol</source>
                  <year>2018</year>
                  <volume>17</volume>
                  <issue>10</issue>
                  <fpage>885</fpage>
                  <lpage>894</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30253-9</pub-id>
                  <?supplied-pmid 30120039?>
                  <pub-id pub-id-type="pmid">30120039</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Steiner</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Beer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Christensen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Cordonnier</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Csiba</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Forsting</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Harnof</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Klijn</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Krieger</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage</article-title>
                  <source>Int J Stroke</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <issue>7</issue>
                  <fpage>840</fpage>
                  <lpage>855</lpage>
                  <pub-id pub-id-type="doi">10.1111/ijs.12309</pub-id>
                  <?supplied-pmid 25156220?>
                  <pub-id pub-id-type="pmid">25156220</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hemphill</surname>
                      <given-names>JC</given-names>
                      <suffix>3rd</suffix>
                    </name>
                    <name>
                      <surname>Greenberg</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Becker</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Bendok</surname>
                      <given-names>BR</given-names>
                    </name>
                    <name>
                      <surname>Cushman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Fung</surname>
                      <given-names>GL</given-names>
                    </name>
                    <name>
                      <surname>Goldstein</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Macdonald</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>PH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>
                  <source>Stroke</source>
                  <year>2015</year>
                  <volume>46</volume>
                  <issue>7</issue>
                  <fpage>2032</fpage>
                  <lpage>2060</lpage>
                  <pub-id pub-id-type="doi">10.1161/STR.0000000000000069</pub-id>
                  <?supplied-pmid 26022637?>
                  <pub-id pub-id-type="pmid">26022637</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Asch</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Luitse</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Rinkel</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>van der Tweel</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Algra</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Klijn</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis</article-title>
                  <source>Lancet Neurol</source>
                  <year>2010</year>
                  <volume>9</volume>
                  <issue>2</issue>
                  <fpage>167</fpage>
                  <lpage>176</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70340-0</pub-id>
                  <?supplied-pmid 20056489?>
                  <pub-id pub-id-type="pmid">20056489</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Balami</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Buchan</surname>
                      <given-names>AM</given-names>
                    </name>
                  </person-group>
                  <article-title>Complications of intracerebral haemorrhage</article-title>
                  <source>Lancet Neurol</source>
                  <year>2012</year>
                  <volume>11</volume>
                  <issue>1</issue>
                  <fpage>101</fpage>
                  <lpage>118</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70264-2</pub-id>
                  <?supplied-pmid 22172625?>
                  <pub-id pub-id-type="pmid">22172625</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chapman</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Huxley</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bousser</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Colman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Donnan</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Neal</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial</article-title>
                  <source>Stroke</source>
                  <year>2004</year>
                  <volume>35</volume>
                  <issue>1</issue>
                  <fpage>116</fpage>
                  <lpage>121</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.STR.0000106480.76217.6F</pub-id>
                  <?supplied-pmid 14671247?>
                  <pub-id pub-id-type="pmid">14671247</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>PROGRESS Collaborative Group</collab>
                  </person-group>
                  <article-title>Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack</article-title>
                  <source>Lancet</source>
                  <year>2001</year>
                  <volume>358</volume>
                  <issue>9287</issue>
                  <fpage>1033</fpage>
                  <lpage>1041</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(01)06178-5</pub-id>
                  <pub-id pub-id-type="pmid">11589932</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ding</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Yin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Mo</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wei</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: a meta-analysis of cohort studies</article-title>
                  <source>J Neurol Sci</source>
                  <year>2018</year>
                  <volume>384</volume>
                  <fpage>133</fpage>
                  <lpage>138</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jns.2017.11.009</pub-id>
                  <?supplied-pmid 29153510?>
                  <pub-id pub-id-type="pmid">29153510</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flynn</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>MacDonald</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>MacWalter</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Doney</surname>
                      <given-names>AS</given-names>
                    </name>
                  </person-group>
                  <article-title>Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage</article-title>
                  <source>Stroke</source>
                  <year>2010</year>
                  <volume>41</volume>
                  <issue>11</issue>
                  <fpage>2606</fpage>
                  <lpage>2611</lpage>
                  <pub-id pub-id-type="doi">10.1161/STROKEAHA.110.589143</pub-id>
                  <?supplied-pmid 20947854?>
                  <pub-id pub-id-type="pmid">20947854</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Biffi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Halpin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Towfighi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gilson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Busl</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Rost</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Greenberg</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Rosand</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Viswanathan</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy</article-title>
                  <source>Neurology</source>
                  <year>2010</year>
                  <volume>75</volume>
                  <issue>8</issue>
                  <fpage>693</fpage>
                  <lpage>698</lpage>
                  <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181eee40f</pub-id>
                  <?supplied-pmid 20733144?>
                  <pub-id pub-id-type="pmid">20733144</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chong</surname>
                      <given-names>BH</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Pong</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>Zuo</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Lui</surname>
                      <given-names>WM</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Tse</surname>
                      <given-names>HF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Use of aspirin in Chinese after recovery from primary intracranial haemorrhage</article-title>
                  <source>Thromb Haemost</source>
                  <year>2012</year>
                  <volume>107</volume>
                  <issue>2</issue>
                  <fpage>241</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="doi">10.1160/TH11-06-0439</pub-id>
                  <?supplied-pmid 22187066?>
                  <pub-id pub-id-type="pmid">22187066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Teo</surname>
                      <given-names>KC</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Mak</surname>
                      <given-names>RH</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>HY</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Tse</surname>
                      <given-names>MY</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Siu</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Cheung</surname>
                      <given-names>RT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antiplatelet resumption after antiplatelet-related intracerebral hemorrhage: a retrospective hospital-based study</article-title>
                  <source>World Neurosurg</source>
                  <year>2017</year>
                  <volume>106</volume>
                  <fpage>85</fpage>
                  <lpage>91</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.wneu.2017.06.015</pub-id>
                  <?supplied-pmid 28606579?>
                  <pub-id pub-id-type="pmid">28606579</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gonzalez-Perez</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gaist</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>de Abajo</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>Saez</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Garcia Rodriguez</surname>
                      <given-names>LA</given-names>
                    </name>
                  </person-group>
                  <article-title>Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival</article-title>
                  <source>Thromb Haemost</source>
                  <year>2017</year>
                  <volume>117</volume>
                  <issue>12</issue>
                  <fpage>2396</fpage>
                  <lpage>2405</lpage>
                  <pub-id pub-id-type="doi">10.1160/TH17-05-0342</pub-id>
                  <?supplied-pmid 29212127?>
                  <pub-id pub-id-type="pmid">29212127</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Glasziou</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Rawlins</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>McCulloch</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>When are randomised trials unnecessary? Picking signal from noise</article-title>
                  <source>BMJ</source>
                  <year>2007</year>
                  <volume>334</volume>
                  <issue>7589</issue>
                  <fpage>349</fpage>
                  <lpage>351</lpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.39070.527986.68</pub-id>
                  <?supplied-pmid 17303884?>
                  <pub-id pub-id-type="pmid">17303884</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perry</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Berge</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bowditch</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Forfang</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Ronning</surname>
                      <given-names>OM</given-names>
                    </name>
                    <name>
                      <surname>Hankey</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Villanueva</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Antithrombotic treatment after stroke due to intracerebral haemorrhage</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2017</year>
                  <volume>5</volume>
                  <fpage>CD012144</fpage>
                  <?supplied-pmid 28540976?>
                  <pub-id pub-id-type="pmid">28540976</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Al-Shahi Salman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Dennis</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Innes</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Drever</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dinsmore</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Whiteley</surname>
                      <given-names>WN</given-names>
                    </name>
                    <name>
                      <surname>Sandercock</surname>
                      <given-names>PAG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial</article-title>
                  <source>Trials</source>
                  <year>2018</year>
                  <volume>19</volume>
                  <fpage>162</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13063-018-2542-6</pub-id>
                  <?supplied-pmid 29506580?>
                  <pub-id pub-id-type="pmid">29506580</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Counsell</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Dennis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>McDowall</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Warlow</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Predicting outcome after acute and subacute stroke: development and validation of new prognostic models</article-title>
                  <source>Stroke</source>
                  <year>2002</year>
                  <volume>33</volume>
                  <issue>4</issue>
                  <fpage>1041</fpage>
                  <lpage>1047</lpage>
                  <pub-id pub-id-type="doi">10.1161/hs0402.105909</pub-id>
                  <?supplied-pmid 11935058?>
                  <pub-id pub-id-type="pmid">11935058</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peto</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pike</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Armitage</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Breslow</surname>
                      <given-names>NE</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Howard</surname>
                      <given-names>SV</given-names>
                    </name>
                    <name>
                      <surname>Mantel</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>McPherson</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Peto</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>PG</given-names>
                    </name>
                  </person-group>
                  <article-title>Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design</article-title>
                  <source>Br J Cancer</source>
                  <year>1976</year>
                  <volume>34</volume>
                  <issue>6</issue>
                  <fpage>585</fpage>
                  <lpage>612</lpage>
                  <pub-id pub-id-type="doi">10.1038/bjc.1976.220</pub-id>
                  <?supplied-pmid 795448?>
                  <pub-id pub-id-type="pmid">795448</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haybittle</surname>
                      <given-names>JL</given-names>
                    </name>
                  </person-group>
                  <article-title>Repeated assessment of results in clinical trials of cancer treatment</article-title>
                  <source>Br J Radiol</source>
                  <year>1971</year>
                  <volume>44</volume>
                  <issue>526</issue>
                  <fpage>793</fpage>
                  <lpage>797</lpage>
                  <pub-id pub-id-type="doi">10.1259/0007-1285-44-526-793</pub-id>
                  <?supplied-pmid 4940475?>
                  <pub-id pub-id-type="pmid">4940475</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peto</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pike</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Armitage</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Breslow</surname>
                      <given-names>NE</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Howard</surname>
                      <given-names>SV</given-names>
                    </name>
                    <name>
                      <surname>Mantel</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>McPherson</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Peto</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>PG</given-names>
                    </name>
                  </person-group>
                  <article-title>Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples</article-title>
                  <source>Br J Cancer</source>
                  <year>1977</year>
                  <volume>35</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1038/bjc.1977.1</pub-id>
                  <?supplied-pmid 831755?>
                  <pub-id pub-id-type="pmid">831755</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maxwell</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>MacLeod</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Joyson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ramadan</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bellfield</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>McGhee</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rudd</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study</article-title>
                  <source>Trials</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <fpage>162</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13063-017-1909-4</pub-id>
                  <?supplied-pmid 28381307?>
                  <pub-id pub-id-type="pmid">28381307</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Clark</surname>
                      <given-names>TG</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>De Stavola</surname>
                      <given-names>BL</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantification of the completeness of follow-up</article-title>
                  <source>Lancet</source>
                  <year>2002</year>
                  <volume>359</volume>
                  <issue>9314</issue>
                  <fpage>1309</fpage>
                  <lpage>1310</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(02)08272-7</pub-id>
                  <?supplied-pmid 11965278?>
                  <pub-id pub-id-type="pmid">11965278</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rodrigues</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Samarasekera</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Lerpiniere</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Humphreys</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>McCarron</surname>
                      <given-names>MO</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Nicoll</surname>
                      <given-names>JAR</given-names>
                    </name>
                    <name>
                      <surname>Sudlow</surname>
                      <given-names>CLM</given-names>
                    </name>
                    <name>
                      <surname>Cordonnier</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wardlaw</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study</article-title>
                  <source>Lancet Neurol</source>
                  <year>2018</year>
                  <volume>17</volume>
                  <issue>3</issue>
                  <fpage>232</fpage>
                  <lpage>240</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30006-1</pub-id>
                  <?supplied-pmid 29331631?>
                  <pub-id pub-id-type="pmid">29331631</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hicks</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Mahaffey</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Mehran</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nissen</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Wiviott</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Dunn</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Solomon</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Marler</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Teerlink</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Farb</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2017 Cardiovascular and stroke endpoint definitions for clinical trials</article-title>
                  <source>Circulation</source>
                  <year>2018</year>
                  <volume>137</volume>
                  <issue>9</issue>
                  <fpage>961</fpage>
                  <lpage>972</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.033502</pub-id>
                  <?supplied-pmid 29483172?>
                  <pub-id pub-id-type="pmid">29483172</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mehran</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Rao</surname>
                      <given-names>SV</given-names>
                    </name>
                    <name>
                      <surname>Bhatt</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Gibson</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Caixeta</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Eikelboom</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kaul</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wiviott</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Menon</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Nikolsky</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium</article-title>
                  <source>Circulation</source>
                  <year>2011</year>
                  <volume>123</volume>
                  <issue>23</issue>
                  <fpage>2736</fpage>
                  <lpage>2747</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.009449</pub-id>
                  <?supplied-pmid 21670242?>
                  <pub-id pub-id-type="pmid">21670242</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Close</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hess</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Baute</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Switzer</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Waller</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Nichols</surname>
                      <given-names>FT</given-names>
                    </name>
                  </person-group>
                  <article-title>Improving modified Rankin Scale assessment with a simplified questionnaire</article-title>
                  <source>Stroke</source>
                  <year>2010</year>
                  <volume>41</volume>
                  <issue>5</issue>
                  <fpage>1048</fpage>
                  <lpage>1050</lpage>
                  <pub-id pub-id-type="doi">10.1161/STROKEAHA.109.571562</pub-id>
                  <?supplied-pmid 20224060?>
                  <pub-id pub-id-type="pmid">20224060</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dennis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mead</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Doubal</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Graham</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Determining the modified Rankin score after stroke by postal and telephone questionnaires</article-title>
                  <source>Stroke</source>
                  <year>2012</year>
                  <volume>43</volume>
                  <issue>3</issue>
                  <fpage>851</fpage>
                  <lpage>853</lpage>
                  <pub-id pub-id-type="doi">10.1161/STROKEAHA.111.639708</pub-id>
                  <?supplied-pmid 22135076?>
                  <pub-id pub-id-type="pmid">22135076</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Akinwuntan</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Close</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Baute</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Aryal</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Brooks</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hess</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Switzer</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life</article-title>
                  <source>Stroke</source>
                  <year>2011</year>
                  <volume>42</volume>
                  <issue>8</issue>
                  <fpage>2276</fpage>
                  <lpage>2279</lpage>
                  <pub-id pub-id-type="doi">10.1161/STROKEAHA.111.613273</pub-id>
                  <?supplied-pmid 21680905?>
                  <pub-id pub-id-type="pmid">21680905</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ford</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>McCowan</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Packard</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study</article-title>
                  <source>Circulation</source>
                  <year>2016</year>
                  <volume>133</volume>
                  <issue>11</issue>
                  <fpage>1073</fpage>
                  <lpage>1080</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.019014</pub-id>
                  <?supplied-pmid 26864092?>
                  <pub-id pub-id-type="pmid">26864092</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Royston</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Parmar</surname>
                      <given-names>MK</given-names>
                    </name>
                  </person-group>
                  <article-title>The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt</article-title>
                  <source>Stat Med</source>
                  <year>2011</year>
                  <volume>30</volume>
                  <issue>19</issue>
                  <fpage>2409</fpage>
                  <lpage>2421</lpage>
                  <pub-id pub-id-type="doi">10.1002/sim.4274</pub-id>
                  <?supplied-pmid 21611958?>
                  <pub-id pub-id-type="pmid">21611958</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gamble</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Krishan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stocken</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Juszczak</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Dore</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Williamson</surname>
                      <given-names>PR</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lim</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Guidelines for the content of statistical analysis plans in clinical trials</article-title>
                  <source>JAMA</source>
                  <year>2017</year>
                  <volume>318</volume>
                  <issue>23</issue>
                  <fpage>2337</fpage>
                  <lpage>2343</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2017.18556</pub-id>
                  <?supplied-pmid 29260229?>
                  <pub-id pub-id-type="pmid">29260229</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
